Nemaura Medical to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021
05/04/2021 - 04:10 PM
Loughborough, England, May 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.
Chief Executive Officer Faz Chowdhury, Ph.D. will deliver his corporate presentation at 3:15pm ET on May 14, 2021.
Investors can also request a one-on-one meeting with Dr. Chowdhury to be arranged following the conclusion of the conference.
Investors can register for the conference here: https://www.benzinga.com/events/small-cap/global/
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™ . sugarBEAT® , a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT® diabetes program.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50 + billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com .
Contact:
Jules Abrahamjulesa@coreir.com
NMRD Rankings
N/A Ranked by Stock Gains
NMRD Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
New York
About NMRD
nemaura medical inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. the company provides sugarbeat, a non-invasive continuous glucose monitoring device for use by persons with type i and type ii diabetes, as well as for screening pre-diabetic patients. it has a license agreement with healthimation, llc, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for type 2 diabetes, prediabetes, and general wellness; the why wait app; and common law trademarks which incorporate the mark why wait or whywait and the use of licensed marks. nemaura medical inc. was founded in 2009 and is based in new york, new york.
